X4 Pharmaceuticals, Inc. (XFOR) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Invivyd, Inc.

Carisma Therapeutics, Inc.

Stoke Therapeutics, Inc.

X4 Pharmaceuticals, Inc.

Foghorn Therapeutics, Inc.

Fate Therapeutics, Inc.

Taysha Gene Therapies, Inc.

Vigil Neuroscience, Inc.

Larimar Therapeutics, Inc.

Neoleukin Therapeutics, Inc.

Ikena Oncology, Inc.

Why is X4 Pharmaceuticals, Inc. ?

Flat results in Jun 25

PRE-TAX PROFIT(Q) At USD -28.35 MM has Fallen at -140.13%
NET PROFIT(Q) At USD -28.38 MM has Fallen at -140.19%
DEBT-EQUITY RATIO (HY) Highest at 379.58 %

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -62.26%, its profits have risen by 90.8%

Reducing Promoter Confidence

Promoters have decreased their stake in the company by -2.2% over the previous quarter and currently hold 26.16% of the company
Promoters decreasing their stake may signify reduced confidence in the future of the business

Underperformed the market in the last 1 year

Even though the market (S&P 500) has generated returns of 12.33% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -62.26% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is X4 Pharmaceuticals, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

X4 Pharmaceuticals, Inc.

-65.75%

0.10

2723.35%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

61.31%

EBIT Growth (5y)

-168.67%

EBIT to Interest (avg)

-19.27

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.44

Sales to Capital Employed (avg)

0.15

Tax Ratio

2.18%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

81.51%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.08

EV to EBIT

-0.13

EV to EBITDA

-0.13

EV to Capital Employed

1.15

EV to Sales

0.47

PEG Ratio

Dividend Yield

ROCE (Latest)

-878.57%

ROE (Latest)

-46.83%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bullish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

16What is working for the Company

NET SALES(HY)

Higher at USD 30.78 MM

NET PROFIT(HY)

Higher at USD -37.77 MM

RAW MATERIAL COST(Y)

Fallen by -336.6% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 3.1 times

DEBTORS TURNOVER RATIO(HY)

Highest at 24.11 times

-17What is not working for the Company

PRE-TAX PROFIT(Q)

At USD -28.35 MM has Fallen at -140.13%

NET PROFIT(Q)

At USD -28.38 MM has Fallen at -140.19%

DEBT-EQUITY RATIO (HY)

Highest at 379.58 %

Here's what is working for X4 Pharmaceuticals, Inc.

Net Sales

At USD 30.78 MM has Grown at 5,367.14%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (USD MM)

Net Sales

Higher at USD 30.78 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the half year the company has already crossed sales of the previous twelve months

Net Sales (USD MM)

Inventory Turnover Ratio

Highest at 3.1 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio

Highest at 24.11 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -336.6% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for X4 Pharmaceuticals, Inc.

Pre-Tax Profit

At USD -28.35 MM has Fallen at -140.13%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD -28.38 MM has Fallen at -140.19%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Debt-Equity Ratio

Highest at 379.58 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio